An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim resultsVignesh T. Packiam, Gary D. Steinberg, William R. Clark et al.|Urologic Oncology Seminars and Original Investigations|2017Cited by 250
Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)Nizar M. Tannir, Oleg Karyakin, Maria Nirvana Formiga et al.|Journal of Clinical Oncology|2024Cited by 26